Passage Bio (PASG) Competitors $6.38 +0.77 (+13.73%) Closing price 08/13/2025 04:00 PM EasternExtended Trading$6.52 +0.14 (+2.19%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PASG vs. MNOV, GNTA, IMA, ARTV, QNTM, ATRA, STRO, ASRT, PYXS, and INCRShould you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include MediciNova (MNOV), Genenta Science (GNTA), Ikena Oncology (IMA), Artiva Biotherapeutics (ARTV), Quantum Biopharma (QNTM), Atara Biotherapeutics (ATRA), Sutro Biopharma (STRO), Assertio (ASRT), Pyxis Oncology (PYXS), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry. Passage Bio vs. Its Competitors MediciNova Genenta Science Ikena Oncology Artiva Biotherapeutics Quantum Biopharma Atara Biotherapeutics Sutro Biopharma Assertio Pyxis Oncology InterCure MediciNova (NASDAQ:MNOV) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability. Does the media refer more to MNOV or PASG? In the previous week, Passage Bio had 6 more articles in the media than MediciNova. MarketBeat recorded 7 mentions for Passage Bio and 1 mentions for MediciNova. Passage Bio's average media sentiment score of 0.94 beat MediciNova's score of 0.93 indicating that Passage Bio is being referred to more favorably in the news media. Company Overall Sentiment MediciNova Positive Passage Bio Positive Do analysts rate MNOV or PASG? MediciNova presently has a consensus target price of $7.00, suggesting a potential upside of 451.18%. Passage Bio has a consensus target price of $140.00, suggesting a potential upside of 2,094.36%. Given Passage Bio's higher possible upside, analysts plainly believe Passage Bio is more favorable than MediciNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Passage Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in MNOV or PASG? 9.9% of MediciNova shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 13.6% of MediciNova shares are held by company insiders. Comparatively, 5.0% of Passage Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, MNOV or PASG? MediciNova has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Is MNOV or PASG more profitable? MediciNova's return on equity of -20.77% beat Passage Bio's return on equity.Company Net Margins Return on Equity Return on Assets MediciNovaN/A -20.77% -19.68% Passage Bio N/A -94.40%-56.82% Which has better valuation and earnings, MNOV or PASG? MediciNova has higher revenue and earnings than Passage Bio. MediciNova is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediciNova$1MN/A-$11.04M-$0.23-5.52Passage BioN/AN/A-$64.77M-$20.40-0.31 SummaryMediciNova beats Passage Bio on 8 of the 15 factors compared between the two stocks. Get Passage Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PASG vs. The Competition Export to ExcelMetricPassage BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.50M$3.03B$5.54B$9.82BDividend YieldN/A2.27%4.62%4.12%P/E Ratio-0.3520.6730.0926.02Price / SalesN/A362.11461.38112.87Price / CashN/A42.0537.7558.93Price / Book0.327.638.506.06Net Income-$64.77M-$54.65M$3.26B$265.11M7 Day Performance12.82%5.41%4.21%3.38%1 Month Performance-6.04%7.14%4.67%2.28%1 Year Performance-57.44%31.27%35.23%29.67% Passage Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PASGPassage Bio3.9442 of 5 stars$6.38+13.7%$140.00+2,094.4%-59.3%$17.50MN/A-0.35130News CoverageEarnings ReportAnalyst ForecastMNOVMediciNova2.5573 of 5 stars$1.35-5.6%$7.00+418.5%+12.4%$70.14M$1M-5.8710Gap DownGNTAGenenta Science2.7723 of 5 stars$3.77-1.4%$25.00+564.0%-28.9%$69.87MN/A0.007IMAIkena Oncology3.3849 of 5 stars$16.60-3.9%$35.50+113.9%-29.6%$69.46M$9.16M-2.1670Gap DownARTVArtiva Biotherapeutics2.5237 of 5 stars$3.01+6.4%$17.80+491.4%-76.2%$68.95M$250K0.0081Analyst RevisionQNTMQuantum BiopharmaN/A$27.80+17.3%N/AN/A$68.91MN/A-1.74N/AATRAAtara Biotherapeutics4.2841 of 5 stars$11.32-2.0%$20.00+76.7%+51.2%$68.85M$128.94M-3.04330Positive NewsEarnings ReportSTROSutro Biopharma3.9359 of 5 stars$0.83+2.1%$6.11+639.2%-76.0%$68.41M$62.04M-0.28240Earnings ReportAnalyst ForecastASRTAssertio2.1636 of 5 stars$0.72+1.1%$2.63+264.5%-26.8%$68.24M$124.96M-2.2520News CoverageEarnings ReportAnalyst ForecastPYXSPyxis Oncology2.4774 of 5 stars$1.10flat$9.00+718.2%-69.2%$68.14MN/A-0.6960Gap DownINCRInterCure0.6736 of 5 stars$1.50+4.2%N/A-15.9%$65.62M$238.85M0.00350Upcoming EarningsGap Up Related Companies and Tools Related Companies MNOV Alternatives GNTA Alternatives IMA Alternatives ARTV Alternatives QNTM Alternatives ATRA Alternatives STRO Alternatives ASRT Alternatives PYXS Alternatives INCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PASG) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredD.C.’s secret plan to crush the debt.At a recent gathering with some of the most powerful people in America, Jeff discovered the Trump administrati...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access